MX394605B - Uso de compuestos de cloroquina y clemizol para el tratamiento de afecciones inflamatorias y cancerosas. - Google Patents
Uso de compuestos de cloroquina y clemizol para el tratamiento de afecciones inflamatorias y cancerosas.Info
- Publication number
- MX394605B MX394605B MX2017016681A MX2017016681A MX394605B MX 394605 B MX394605 B MX 394605B MX 2017016681 A MX2017016681 A MX 2017016681A MX 2017016681 A MX2017016681 A MX 2017016681A MX 394605 B MX394605 B MX 394605B
- Authority
- MX
- Mexico
- Prior art keywords
- chloroquine
- treatment
- clemizol
- inflammatory
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/14—Radicals substituted by nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562187061P | 2015-06-30 | 2015-06-30 | |
| PCT/US2016/040566 WO2017004454A1 (en) | 2015-06-30 | 2016-06-30 | Use of chloroquine and clemizole compounds for treatment of inflammatory and cancerous conditions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017016681A MX2017016681A (es) | 2018-07-06 |
| MX394605B true MX394605B (es) | 2025-03-24 |
Family
ID=57609247
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017016681A MX394605B (es) | 2015-06-30 | 2016-06-30 | Uso de compuestos de cloroquina y clemizol para el tratamiento de afecciones inflamatorias y cancerosas. |
| MX2022008100A MX2022008100A (es) | 2015-06-30 | 2017-12-18 | Uso de compuestos de cloroquina y clemizol para el tratamiento de afecciones inflamatorias y cancerosas. |
| MX2023003792A MX2023003792A (es) | 2015-06-30 | 2017-12-18 | Uso de compuestos de cloroquina y clemizol para el tratamiento de afecciones inflamatorias y cancerosas. |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022008100A MX2022008100A (es) | 2015-06-30 | 2017-12-18 | Uso de compuestos de cloroquina y clemizol para el tratamiento de afecciones inflamatorias y cancerosas. |
| MX2023003792A MX2023003792A (es) | 2015-06-30 | 2017-12-18 | Uso de compuestos de cloroquina y clemizol para el tratamiento de afecciones inflamatorias y cancerosas. |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US10688083B2 (enExample) |
| EP (1) | EP3317274A4 (enExample) |
| JP (3) | JP7068827B2 (enExample) |
| KR (3) | KR20230129590A (enExample) |
| CN (2) | CN107922404B (enExample) |
| AU (4) | AU2016288699B2 (enExample) |
| CA (3) | CA3294570A1 (enExample) |
| HK (1) | HK1249508A1 (enExample) |
| IL (4) | IL300476B2 (enExample) |
| MX (3) | MX394605B (enExample) |
| NZ (1) | NZ776616A (enExample) |
| TW (3) | TWI771272B (enExample) |
| WO (1) | WO2017004454A1 (enExample) |
| ZA (2) | ZA201708471B (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3294570A1 (en) * | 2015-06-30 | 2026-03-02 | Eiger Group International, Inc. | Use of r-chloroquine or metabolites, r-rhydroxychloroquine or metabolites, or deuterated analogs of r-chloroquine or rhydroxychloroquine, in treatment of liver inflammation |
| GB201702160D0 (en) | 2017-02-09 | 2017-03-29 | Univ Leeds Innovations Ltd | Inhibitors for use in therapy |
| CN106831571A (zh) * | 2017-02-13 | 2017-06-13 | 中卫市创科知识产权投资有限公司 | 一种硫酸氯喹生产工艺 |
| CA3082591A1 (en) * | 2017-11-15 | 2019-05-23 | Beth Israel Deaconess Medical Center, Inc. | Markers for the diagnosis and treatment of non-alcoholic steatohepatitis (nash) and advanced liver fibrosis |
| CN113354581B (zh) * | 2020-03-06 | 2023-06-20 | 华南理工大学 | 手性氯喹及其磷酸盐的制备方法及其应用 |
| CN113527201A (zh) * | 2020-04-14 | 2021-10-22 | 瀚海新拓(杭州)生物医药有限公司 | 光学活性氯喹和羟氯喹及其类似物、其制备方法、组合物和用途 |
| WO2021217574A1 (en) * | 2020-04-30 | 2021-11-04 | Waterstone Pharmaceuticals (Wuhan) Co., Ltd. | Treatment or prevention of coronaviridae infection |
| CN111551645B (zh) * | 2020-04-30 | 2022-11-08 | 上海中西三维药业有限公司 | 一种硫酸羟氯喹有关物质的检测方法及其应用 |
| CN111909087A (zh) * | 2020-06-15 | 2020-11-10 | 珠海润都制药股份有限公司 | 一种手性氨基氯喹啉的制备方法 |
| CN111662229B (zh) * | 2020-07-08 | 2023-03-24 | 精华制药集团南通有限公司 | 一种磷酸氯喹的制备工艺 |
| CN111793026A (zh) * | 2020-07-23 | 2020-10-20 | 珠海润都制药股份有限公司 | 一种硫酸羟氯喹及其对映体的晶型和制备方法 |
| CN114057640A (zh) * | 2020-08-05 | 2022-02-18 | 凯特立斯（深圳）科技有限公司 | 一种光学纯(r)/(s)-羟氯喹侧链的不对称合成方法 |
| CN112225697B (zh) * | 2020-10-16 | 2023-01-03 | 宁波大学 | 一种对映体纯氯喹及磷酸氯喹的制备方法 |
| CN114573464A (zh) * | 2022-03-02 | 2022-06-03 | 重庆南松凯博生物制药有限公司 | 一种羟氯喹侧链精制方法 |
| CN116327749A (zh) * | 2023-04-21 | 2023-06-27 | 重庆医科大学 | Gw9662制备治疗非酒精性脂肪性肝炎药物的应用 |
| CN117466821A (zh) * | 2023-10-25 | 2024-01-30 | 中化医药有限公司 | 一种盐酸克立咪唑的工艺制备方法 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4181725A (en) | 1977-05-02 | 1980-01-01 | The Regents Of The University Of Michigan | Method for alleviating psoriasis |
| WO1998017231A2 (en) | 1996-10-18 | 1998-04-30 | Charous B Lauren | Treatment and delivery of hydroxychloroquine |
| CA2372443C (en) * | 1999-04-30 | 2010-07-13 | Apt Pharmaceuticals, L.L.C. | Local administration of anti-malarial agents for the treatment of inflammatory diseases |
| US20060014786A1 (en) * | 2002-05-17 | 2006-01-19 | Rajeev Raut | Opthalmic pharmaceutical compositions and methods for treating ocular inflammation |
| WO2003103586A2 (en) | 2002-06-05 | 2003-12-18 | Coley Pharmaceutical Group, Inc. | Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory cpg nucleic acids |
| TW200902047A (en) | 2003-02-14 | 2009-01-16 | Combinatorx Inc | Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines |
| ZA200505996B (en) * | 2003-02-14 | 2006-12-27 | Combinatorx Inc | Combination therapy for the treatment of immunoinflammatory disorders |
| AU2003219160A1 (en) * | 2003-03-12 | 2004-09-30 | Molecular Engines Laboratories Sa | Methods and compositions for the treatment of cancer |
| TW200522932A (en) * | 2003-09-15 | 2005-07-16 | Combinatorx Inc | Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines |
| CN1893978A (zh) | 2003-10-27 | 2007-01-10 | 沃泰克斯药物股份有限公司 | 用于hcv治疗的组合 |
| SE0500055D0 (sv) * | 2005-01-10 | 2005-01-10 | Astrazeneca Ab | Therapeutic agents 3 |
| CN101193622A (zh) | 2005-06-09 | 2008-06-04 | 比奥里波克斯公司 | 治疗炎性疾病的方法和组合物 |
| EP1888033B1 (en) * | 2005-06-09 | 2014-02-19 | Meda AB | Method and composition for treating inflammatory disorders |
| MX2008010355A (es) | 2006-02-09 | 2008-10-31 | Schering Corp | Combinaciones que comprenden inhibidores de proteasa del virus de la hepatitis c e inhibidores de polimerasa del virus de la hepatitis c, y metodos de tratamiento relacionados con los mismos. |
| WO2009039248A2 (en) * | 2007-09-18 | 2009-03-26 | Stanford University | Methods of treating a flaviviridae family viral infection and compositions for treating a flaviviridae family viral infection |
| US9101628B2 (en) * | 2007-09-18 | 2015-08-11 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and composition of treating a flaviviridae family viral infection |
| EP2188630A4 (en) * | 2007-10-02 | 2010-11-03 | Univ Rochester | METHODS AND COMPOSITIONS RELATED TO SYNERGISTIC ANSWERS TO ONCOGENIC MUTATIONS |
| US20120114670A1 (en) | 2007-10-02 | 2012-05-10 | University Of Rochester | Methods and compositions related to synergistic responses to oncogenic mutations |
| US20120082659A1 (en) * | 2007-10-02 | 2012-04-05 | Hartmut Land | Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations |
| CL2009000647A1 (es) * | 2008-04-04 | 2010-06-04 | Chugai Pharmaceutical Co Ltd | Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto. |
| US20090312302A1 (en) * | 2008-06-17 | 2009-12-17 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating nonalcoholic fatty liver disease-associated disorders |
| CN102448458B (zh) * | 2009-03-18 | 2015-07-22 | 小利兰·斯坦福大学理事会 | 治疗黄病毒科病毒感染的方法和组合物 |
| HUE052510T2 (hu) * | 2009-05-27 | 2021-05-28 | Ptc Therapeutics Inc | Módszerek a rák és a nem daganatos állapotok kezelésére |
| CN102548393B (zh) * | 2009-07-31 | 2015-06-03 | 斯特里克再生医学学院,斯特里克学院事务所 | 脂肪性肝炎-肝癌模型动物 |
| KR20180036810A (ko) * | 2009-08-14 | 2018-04-09 | 레비비코르 인코포레이션 | 당뇨병 치료를 위한 복수 형질전환 돼지 |
| US9415046B2 (en) * | 2009-09-29 | 2016-08-16 | Yale University | Compositions and methods for inhibiting inflammation from and rejection of biomaterials and other methods |
| US20120202849A1 (en) | 2009-10-12 | 2012-08-09 | Anil Pareek | Pharmaceutical compositions for the treatment/prophylaxis of non-alcoholic fatty liver disease |
| US9700560B2 (en) * | 2009-11-16 | 2017-07-11 | University Of Georgia Research Foundation, Inc. | 2′-fluoro-6′-methylene carbocyclic nucleosides and methods of treating viral infections |
| CA2848711C (en) * | 2011-09-16 | 2019-08-06 | Galectin Therapeutics, Inc. | Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease |
| EP2818473A4 (en) * | 2012-02-20 | 2015-04-15 | Takeda Pharmaceutical | HETEROCYCLIC CONNECTION |
| US20130273003A1 (en) * | 2012-04-17 | 2013-10-17 | Vertex Pharmaceuticals Incorporated | Therapies for Treating Hepatitis C Virus Infection |
| MD20140134A2 (ro) | 2012-05-22 | 2015-04-30 | Idenix Pharmaceuticals, Inc. | Compuşi ai D-aminoacizilor pentru tratamentul bolilor hepatice |
| WO2013180149A1 (ja) | 2012-05-30 | 2013-12-05 | 富山化学工業株式会社 | 重水素化含窒素複素環カルボキサミド誘導体またはその塩 |
| WO2014031769A2 (en) | 2012-08-21 | 2014-02-27 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of diseases associated with inflammation |
| JP6146990B2 (ja) | 2012-11-16 | 2017-06-14 | コンサート ファーマシューティカルズ インコーポレイテッド | 重水素化されたｃｆｔｒ増強物質 |
| CN103550242B (zh) | 2013-11-22 | 2015-07-15 | 四川国康药业有限公司 | 一种治疗肝纤维化的药物组合物及其制备方法 |
| JP2017504572A (ja) * | 2013-11-27 | 2017-02-09 | アイデニクス・ファーマシューティカルズ・エルエルシー | 肝臓癌治療のためのヌクレオチド類 |
| JP6367545B2 (ja) | 2013-12-17 | 2018-08-01 | コンサート ファーマシューティカルズ インコーポレイテッド | ルキソリチニブの重水素化誘導体 |
| CA3294570A1 (en) * | 2015-06-30 | 2026-03-02 | Eiger Group International, Inc. | Use of r-chloroquine or metabolites, r-rhydroxychloroquine or metabolites, or deuterated analogs of r-chloroquine or rhydroxychloroquine, in treatment of liver inflammation |
-
2016
- 2016-06-30 CA CA3294570A patent/CA3294570A1/en active Pending
- 2016-06-30 JP JP2017568408A patent/JP7068827B2/ja active Active
- 2016-06-30 KR KR1020237028986A patent/KR20230129590A/ko not_active Ceased
- 2016-06-30 IL IL300476A patent/IL300476B2/en unknown
- 2016-06-30 TW TW105120868A patent/TWI771272B/zh active
- 2016-06-30 NZ NZ776616A patent/NZ776616A/en unknown
- 2016-06-30 IL IL310969A patent/IL310969A/en unknown
- 2016-06-30 TW TW112136665A patent/TWI881480B/zh active
- 2016-06-30 CN CN201680039155.3A patent/CN107922404B/zh active Active
- 2016-06-30 CN CN202110651428.2A patent/CN113274386A/zh active Pending
- 2016-06-30 WO PCT/US2016/040566 patent/WO2017004454A1/en not_active Ceased
- 2016-06-30 TW TW111123545A patent/TWI830262B/zh active
- 2016-06-30 KR KR1020267013371A patent/KR20260077866A/ko active Pending
- 2016-06-30 US US15/738,827 patent/US10688083B2/en active Active
- 2016-06-30 EP EP16818845.6A patent/EP3317274A4/en active Pending
- 2016-06-30 CA CA2989634A patent/CA2989634C/en active Active
- 2016-06-30 AU AU2016288699A patent/AU2016288699B2/en active Active
- 2016-06-30 CA CA3178499A patent/CA3178499C/en active Active
- 2016-06-30 HK HK18109030.3A patent/HK1249508A1/zh unknown
- 2016-06-30 KR KR1020187002620A patent/KR20180032578A/ko not_active Ceased
- 2016-06-30 MX MX2017016681A patent/MX394605B/es unknown
-
2017
- 2017-12-10 IL IL256233A patent/IL256233A/en active IP Right Grant
- 2017-12-13 ZA ZA2017/08471A patent/ZA201708471B/en unknown
- 2017-12-18 MX MX2022008100A patent/MX2022008100A/es unknown
- 2017-12-18 MX MX2023003792A patent/MX2023003792A/es unknown
-
2020
- 2020-05-07 US US16/869,312 patent/US12090141B2/en active Active
- 2020-06-29 ZA ZA2020/04136A patent/ZA202004136B/en unknown
- 2020-11-26 IL IL279020A patent/IL279020B2/en unknown
-
2021
- 2021-02-25 AU AU2021201234A patent/AU2021201234A1/en not_active Abandoned
-
2022
- 2022-05-02 JP JP2022075974A patent/JP7470151B2/ja active Active
-
2023
- 2023-03-07 AU AU2023201397A patent/AU2023201397B2/en active Active
-
2024
- 2024-04-05 JP JP2024061358A patent/JP7810746B2/ja active Active
- 2024-08-12 US US18/800,926 patent/US20240398761A1/en active Pending
- 2024-11-27 AU AU2024266943A patent/AU2024266943A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202004136B (en) | Use of chloroquine and clemizole compounds for treatment of inflammatory and cancerous conditions | |
| IL282663A (en) | Bt1718 for use in treating cancer | |
| CL2018003316A1 (es) | Compuestos para la inhibición de k-ras y para el tratamiento del cáncer. (divisional solicitud 201702786) | |
| EA201990296A1 (ru) | Антитела против siglec-7 для лечения рака | |
| MX2018005315A (es) | Composiciones y metodos para el tratamiento del cancer. | |
| IL268814A (en) | Compositions and methods for treatment of cancer | |
| MX379270B (es) | Composiciones que comprenden cepas bacterianas. | |
| PL3943093T3 (pl) | Zastosowanie pasteryzowanej akkermansia do leczenia nowotworu złośliwego | |
| HUE053191T2 (hu) | 2-Heteroaril-3-oxo-2,3-dihidropiridazin-4-karboxamidok rák kezelésére | |
| EA201691866A1 (ru) | Проникающие в опухоль лимфоциты для адоптивной клеточной терапии | |
| PT2976360T (pt) | Terapia envolvendo anticorpos contra claudina 18.2 para o tratamento de cancro | |
| MX2018004515A (es) | Agentes de anticuerpo especificos para cd19 humano y usos de los mismos. | |
| EA201992251A1 (ru) | Противораковые вакцины и способы лечения с их применением | |
| PT3377516T (pt) | Composição para o tratamento do cancro | |
| PT3142751T (pt) | Anticorpos anti-b7-h1 e anti-ctla-4 para o tratamento de cancro de pulmão de não pequenas células. | |
| DK3624837T3 (da) | Anti-fgfr2-antistoffer i kombination med kemoterapeutiske midler til kræftbehandling | |
| IL269157A (en) | Compositions and methods for treating cancer | |
| PL3490560T3 (pl) | Niraparyb do stosowania w sposobie leczenia nowotworu prostaty | |
| PT3773738T (pt) | Conjugados anticorpos-fármaco e suas utilizações para o tratamento do cancro | |
| CL2019003670A1 (es) | Composición que comprende manosa oligosacárido y proceso para realizarla y uso de esta. | |
| BR112017008799A2 (pt) | composições de apilimod e métodos de uso das mesmas no tratamento de câncer renal | |
| HUE055132T2 (hu) | Virulenciában gyengített baktériumok rosszindulatú szolid tumorok kezelésére | |
| IL281845A (en) | Combination therapy for the treatment of cancer | |
| LT3534885T (lt) | Farneziltransferazės inhibitoriai, skirti naudoti vėžio gydymui | |
| IL281600A (en) | Methods of treating cancer |